Transcriptomics,Genomics

Dataset Information

32

Basal-like phenotype is not associated with patient survival in estrogen receptor negative breast cancers


ABSTRACT: INTRODUCTION: Basal-phenotype or basal-like breast cancers are characterized by basal epithelium cytokeratin (CK5/14/17) expression, negative estrogen receptor (ER) status and distinct gene expression signature. We studied the clinical and biological features of the basal-phenotype tumors determined by immunohistochemistry (IHC) and cDNA microarrays especially within the ER-negative subgroup. METHODS: IHC was used to evaluate the CK5/14 status of 445 stage II breast cancers. The gene expression signature of the CK5/14 immunopositive tumors was investigated within a subset (100) of the breast tumors (including 50 ER-negative tumors) with a cDNA microarray. Survival for basal-phenotype tumors as determined by CK5/14 IHC and gene expression signature was assessed. RESULTS: From the 375 analyzable tumor specimens, 48 (13%) were immunohistochemically positive for CK5/14. We found adverse distant disease-free survival for the CK5/14-positive tumors during the first years (3 years hazard ratio (HR) 2.23, 95% confidence interval (CI) 1.17 to 4.24, p = 0.01; 5 years HR 1.80, 95% CI 1.02 to 3.15, p = 0.04) but the significance was lost at the end of the follow-up period (10 years HR 1.43, 95% CI 0.84 to 2.43, p = 0.19). Gene expression profiles of immunohistochemically determined CK5/14-positive tumors within the ER-negative tumor group implicated 1,713 differently expressed genes (p < 0.05). Hierarchical clustering analysis with the top 500 of these genes formed one basal-like and a non-basal-like cluster also within the ER-negative tumor entity. A highly concordant classification could be constructed with a published gene set (Sorlie's intrinsic gene set, concordance 90%). Both gene sets identified a basal-like cluster that included most of the CK5/14-positive tumors, but also immunohistochemically CK5/14-negative tumors. Within the ER-negative tumor entity there was no survival difference between the non-basal and basal-like tumors as identified by immunohistochemical or gene-expression-based classification. CONCLUSION: Basal cytokeratin-positive tumors have a biologically distinct gene expression signature from other ER-negative tumors. Even if basal cytokeratin expression predicts early relapse among non-selected tumors, the clinical outcome of basal tumors is similar to non-basal ER-negative tumors. Immunohistochemically basal cytokeratin-positive tumors almost always belong to the basal-like gene expression profile, but this cluster also includes few basal cytokeratin-negative tumors. Keywords: Disease state analysis Overall design: 100 breast cancer tumor samples were analyzed on 2-color cDNA microarrays using the Stratagene Universal Human Reference RNA as the common reference sample.

INSTRUMENT(S): Swegene Human 27K RAP UniGene188 array

SUBMITTER: Sofia K Gruvberger-Saal  

PROVIDER: GSE6768 | GEO | 2007-02-26

SECONDARY ACCESSION(S): PRJNA98943

REPOSITORIES: GEO

altmetric image

Publications

Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers.

Jumppanen Mervi M   Gruvberger-Saal Sofia S   Kauraniemi Päivikki P   Tanner Minna M   Bendahl Pär-Ola PO   Lundin Mikael M   Krogh Morten M   Kataja Pasi P   Borg Ake A   Fernö Mårten M   Isola Jorma J  

Breast cancer research : BCR 20070101 1


INTRODUCTION: Basal-phenotype or basal-like breast cancers are characterized by basal epithelium cytokeratin (CK5/14/17) expression, negative estrogen receptor (ER) status and distinct gene expression signature. We studied the clinical and biological features of the basal-phenotype tumors determined by immunohistochemistry (IHC) and cDNA microarrays especially within the ER-negative subgroup. METHODS: IHC was used to evaluate the CK5/14 status of 445 stage II breast cancers. The gene expression  ...[more]

Similar Datasets

2006-09-15 | E-SMDB-2863 | ArrayExpress
2009-03-14 | GSE6367 | GEO
2011-12-21 | E-GEOD-31870 | ArrayExpress
2016-08-21 | E-GEOD-74667 | ArrayExpress
| GSE65407 | GEO
2012-03-09 | E-GEOD-31003 | ArrayExpress
2012-03-20 | E-GEOD-32646 | ArrayExpress
2015-05-19 | E-GEOD-58812 | ArrayExpress
2008-12-03 | GSE13787 | GEO
2010-07-22 | GSE23041 | GEO